octreotide acetate solution for injection
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
58
Go to page
1
2
3
September 09, 2026
Reasonable Treatment Escalation to Combination of Sandostatin, Bevacizumab and Everolimus in Recurrent Meningioma Patients Who Failed Standard and Other Therapies
(SNO 2026)
- No abstract available
Clinical • Brain Cancer • Meningioma • Solid Tumor
May 28, 2026
EORTC 2334 - LUMEN
(EANO 2026)
- No abstract available
Oncology
August 10, 2026
Acromegaly Secondary to Ectopic Growth Hormone-Releasing Hormone Secretion From Metastatic Bronchial Carcinoid Tumor: A Case Report.
(PubMed, Cureus)
- "She also continues to require long-term therapy with octreotide (Sandostatin) and pegvisomant to control IGF-1 levels. This case highlights the rarity of ectopic GHRH secretion from metastatic bronchial carcinoid tumors and emphasizes the importance of long-term surveillance and multidisciplinary management."
Journal • Acromegaly • Carcinoid Tumor • Endocrine Disorders • Lung Cancer • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Solid Tumor • IGF1
July 19, 2026
A Case Report: Fatal Mesenteric Microvascular Compromise Following Methamphetamine use and Insulin Overdose Treated with Octreotide.
(PubMed, S D Med)
- "This case highlights the critical importance of considering methamphetamine use and its potential synergistic effects with medications like octreotide in the management of complex medical conditions to prevent fatal complications such as severe intestinal ischemia."
Journal • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Diabetes • Gastrointestinal Disorder • Metabolic Disorders • Nephrology • Pain • Renal Disease • Severe Hypoglycemia • Type 1 Diabetes Mellitus
April 13, 2026
When Meningioma Travels: Rare Extracranial Metastasis-Case and Review.
(PubMed, Clin Case Rep)
- "Treatment with Sandostatin and Everolimus stabilized the hepatic lesion, although intracranial recurrences persisted and the patient died during a surgical brain resection of a recurrence from a massive intraoperative hemorrhage. Repeated recurrences, high mitotic activity, and histologic transformation may predict metastatic potential. Our review of the last decade identified only a few similar extracranial cases, supporting targeted imaging and individualized therapy in high-risk meningiomas."
Journal • Brain Cancer • Hematological Disorders • Hepatocellular Cancer • Hepatology • Meningioma • Oncology • Solid Tumor
January 22, 2026
Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas
(clinicaltrials.gov)
- P2 | N=2 | Terminated | Sponsor: National Cancer Institute (NCI) | Completed ➔ Terminated; This protocol was terminated prematurely because the prior principal investigator departed the Institute without treating any participants.
Platinum resistant • Trial termination • Breast Cancer • Cervical Cancer • Endometrial Cancer • Epithelial Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor • BRCA • CD4
November 06, 2025
Somatostatin in combination with corticosteroids is effective in B-Thymomas (even) with low Dotatoc-uptake after failure of chemotherapy
(DGHO 2025)
- "Somatostatin/Corticoid-Combination is an effective treatment option in heavily pretreated patients with B-Thymoma. This also works in tumors with rather low dotatoc-uptake (i.e. Somatostatin-receptor expression).However, corticosteroid-side effects are severe despite prophylaxis.*Deutsches Krebsregister 2022"
Combination therapy • Musculoskeletal Diseases • Osteoporosis • Pulmonary Disease • Rare Diseases • Rheumatology • Solid Tumor • Thymic Carcinoma • Thymoma • Thymus Cancer • SSTR
November 03, 2025
Uncommon Origin, Common Presentation: A Rare Case of Mesenteric Carcinoid Tumor Mimicking Functional Gastrointestinal Disorders.
(PubMed, Cureus)
- "Elevated chromogranin A and biopsy confirmed a grade 1 neuroendocrine tumor. This case highlights the importance of considering carcinoid tumors in patients with persistent GI symptoms and emphasizes early recognition, particularly in atypical presentations, to guide timely and effective management."
Journal • Carcinoid Syndrome • Carcinoid Tumor • Endocrine Cancer • Gastroenterology • Gastrointestinal Disorder • Hepatitis C • Hepatology • Infectious Disease • Neuroendocrine Carcinoma • Neuroendocrine Tumor • Oncology • Pain • Solid Tumor • CHGA
November 03, 2025
Challenges in Diagnosis and Management of Ovarian Neuroendocrine Carcinoma: A Case of Aggressive Disease With Multimodal Treatment Approach.
(PubMed, Clin Case Rep)
- "Despite initial treatment with paclitaxel and carboplatin, residual disease persisted, prompting therapy with long-acting Sandostatin. The disease subsequently progressed with hepatic and peritoneal involvement, and she was successfully managed with cisplatin and etoposide. This case illustrates the diagnostic complexity and aggressive course of ovarian neuroendocrine carcinoma and underscores the importance of individualized, multimodal treatment strategies and vigilant follow-up in the absence of standardized guidelines."
Journal • Endocrine Cancer • Gynaecologic Neuroendocrine Carcinoma • Neuroendocrine Carcinoma • Neuroendocrine Tumor • Oncology • Ovarian Cancer • Pain • Solid Tumor
July 01, 2025
PERICARDIAL EFFUSION IN A PATIENT WITH METASTATIC CARCINOID DISEASE TREATED WITH EVEROLIMUS: A CASE REPORT
(CHEST 2025)
- "The patient was treated with everolimus and sandostatins...The patient was treated with colchicine, and after six days of drainage, repeated TTE showed trivial pericardial effusion... The development of a large asymptomatic pericardial effusion in this patient underscores the critical importance of regular cardiac monitoring. Early detection and prompt intervention are crucial for preventing potentially life-threatening complications, such as cardiac tamponade. Future research should focus on establishing optimal cardiac monitoring protocols for patients with carcinoid tumors, especially those receiving mTOR inhibitors, such as everolimus."
Case report • Clinical • Metastases • Carcinoid Syndrome • Carcinoid Tumor • Cardiovascular • Congestive Heart Failure • Heart Failure • Neuroendocrine Tumor • Pulmonary Disease • Solid Tumor
July 01, 2025
PERSISTENT ENDOBRONCHIAL OBSTRUCTION SECONDARY TO A GRADE 2 NEUROENDOCRINE TUMOR
(CHEST 2025)
- "Management was discussed in a multidisciplinary tumor board, and given the high uptake on DOTATATE imaging, the patient was deemed a candidate for somatostatin analog therapy (e.g., Sandostatin [octreotide]) to control disease progression and alleviate symptoms... This case underscores the importance of early evaluation and management of suspicious pulmonary lesions. Advanced imaging modalities such as DOTATATE PET are invaluable for accurate staging and treatment planning in neuroendocrine tumors. Despite their intermediate grade, atypical carcinoid tumors can behave aggressively, necessitating a multidisciplinary approach to achieve optimal patient outcomes."
Carcinoid Tumor • Hepatocellular Cancer • Lung Cancer • Neuroendocrine Tumor • Oncology • Respiratory Diseases • Solid Tumor • CHGA • GAST • NKX2-1 • SYP • TP63
October 16, 2025
Treatment of Orthostatic Intolerance
(clinicaltrials.gov)
- P1/2 | N=150 | Active, not recruiting | Sponsor: Satish R. Raj | Trial completion date: Dec 2027 ➔ Dec 2029 | Trial primary completion date: Dec 2027 ➔ Dec 2029
Trial completion date • Trial primary completion date • Cardiovascular
September 11, 2025
Octreotide and direct/indirect lung injury.
(PubMed, Res Pharm Sci)
- "Keywords including "octreotide" OR "sandostatin" AND "lung injury" OR "ARDS" OR "respiratory distress" OR "lung fibrosis" were searched in the database of PubMed, and 44 articles were found...It appears that octreotide is a protective drug for the treatment of direct and indirect lung injuries, exhibiting anti-inflammatory, anti-hypersecretory, anti-fibrotic, and anti-neutrophil permeability effects, while also increasing endogenous antioxidants. However, there is still room for extensive research to fully clarify the effectiveness of octreotide for direct or indirect lung injury."
Journal • Review • Acute Respiratory Distress Syndrome • Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases
September 01, 2025
A novel SOX5::NTRK3 fusion in a patient with neuroendocrine tumour of the lungs: a case report
(ECP 2025)
- "The patient is currently undergoing treatment with somatostatin analogue (Sandostatin)... This case report describes a novel SOX5::NTRK3 fusion in a pulmonary neuroendocrine tumour, expanding the known spectrum of NTRK3 rearrangements. Its identification underscores the value of molecular profiling and may inform personalized treatment decisions. If standard therapy fails, NTRK inhibitors could offer a targeted alternative."
Case report • Clinical • Carcinoid Tumor • Lung Cancer • Neuroendocrine Tumor • Non Small Cell Lung Cancer • Oncology • Solid Tumor • NTRK • NTRK3 • YBX1
February 24, 2025
Atypical Presentation of Hematopoietic Stem Cell Transplantation Associated Thrombotic Microangiopathy
(ATS 2025)
- "His post-transplant course had been complicated by severe graft-versus-host-disease of the skin and gastrointestinal tract treated with tacrolimus, steroids, sandostatin, and photopheresis. His medications included tacrolimus, sirolimus, prednisone, valacyclovir, posaconazole, meropenem, and linezolid...Primary intervention should be withdrawal of calcineurin inhibitors, and although frequently used, plasma exchange results may vary. Our patient presented with DAH likely as a manifestation of his TMA."
Acute Myelogenous Leukemia • Bone Marrow Transplantation • Cough • Dermatology • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Oncology • Pulmonary Disease • Respiratory Diseases • Thrombosis • Transplantation • HP
May 15, 2025
Octreotide vs. Splenic Artery Ligation for Portal Flow Modulation in Living Donor Liver Transplants (SCALOP Trial)
(clinicaltrials.gov)
- P4 | N=80 | Not yet recruiting | Sponsor: King Faisal Specialist Hospital & Research Center
New P4 trial • Transplantation
April 27, 2025
A Case of Pancreatic Fistula Following Left Nephrectomy: A Rare Complication.
(PubMed, Cureus)
- "The fistula was managed effectively with subcutaneous somatostatin analog (Sandostatin) injections, parenteral nutrition, and a strict nothing by mouth (NPO) regimen. This case underscores the potential risk of pancreatic fistula following radical nephrectomy, highlighting the importance of early diagnosis and appropriate management strategies. Unfortunately, the patient's recovery was complicated by intra-abdominal bleeding and septic shock, which ultimately led to his death."
Journal • Hepatology • Oncology • Renal Cell Carcinoma • Sarcoma • Septic Shock • Solid Tumor • Urothelial Cancer
March 13, 2025
PANasta: Cattell-Warren Versus Blumgart Techniques of Pancreatico-jejunostomy Following Pancreato-duodenectomy
(clinicaltrials.gov)
- P3 | N=295 | Completed | Sponsor: University of Liverpool | Active, not recruiting ➔ Completed | N=506 ➔ 295
Enrollment change • Trial completion • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor
November 21, 2024
Casting a Wide NET: When Is the Optimal Time for 177Lu-Dotatate Treatment?
(PubMed, Oncology (Williston Park))
- "3 Prior to 2017, available treatments for advanced NETs included somatostatin analogues (lanreotide [Somatuline] and octreotide [Sandostatin]), targeted therapy (everolimus [Afinitor] and sunitinib [Sutent]), and chemotherapy. 8 Previously these tumors were placed under the umbrella of poorly differentiated neuroendocrine carcinomas. Given that well-differentiated grade 3 NETs are relatively new, standard-of-care treatment options are undefined."
Journal • Endocrine Cancer • Neuroendocrine Tumor • Oncology • Solid Tumor
October 17, 2024
Effective Control of Pancreatitis-Related Gastric Varices Through Splenic Artery Embolization: A Case Report.
(PubMed, Cureus)
- "The patient initially received medical management with IV sandostatin for bleeding control, and a splenectomy was planned as the definitive management...Splenic artery embolization led to a successful reduction in gastric variceal size and no recurrence of bleeding. This case report presents a case of pancreatitis-induced splenic vein thrombosis (PISVT) and highlights splenic artery embolization as a viable management strategy in such cases."
Journal • Cardiovascular • Gastrointestinal Disorder • Hematological Disorders • Pancreatitis • Thrombosis
October 02, 2024
Treatment of Orthostatic Intolerance
(clinicaltrials.gov)
- P1/2 | N=150 | Active, not recruiting | Sponsor: Satish R. Raj | Trial completion date: Dec 2025 ➔ Dec 2027 | Trial primary completion date: Dec 2025 ➔ Dec 2027
Trial completion date • Trial primary completion date • Cardiovascular
March 17, 2024
CASE REPORT: A PATIENT WITH MULTIPLE PARAGANGLIOMA TREATED WITH LONG-ACTING SOMATOSTATIN ANALOGUE
(ICE-EDEC 2024)
- "Medications : Tresiba insulin 16 units once daily, Lymjuv insulin with all meals, doxazosin 8 mg twice daily, Moxinidine 0.4 mcg twice daily, bisoprolol 5 mg twice daily, aspirin 300 mg once daily, atorvastatin 80 mg once daily. Started on Sandostatin 30 mg once monthly in May 22... A case of recurrent metastatic paraganglioma is presented.After 1 year of treatment with LAR octreotide there is improvement in quality of life, reduction in hypertensive crisis and stroke admissions. Research should be continued for targeting SSTRs with second-generation SSAs,chimeric dual receptor-targeting peptides, chemotactic delivery through SSTRs, and other novel methods."
Clinical • Anemia • Cardiovascular • CNS Tumor • Diabetes • Endocrine Cancer • Gynecology • Hematological Disorders • Metabolic Disorders • Neuroendocrine Tumor • Oncology • Solid Tumor • SSTR
February 14, 2024
Multinuclear 1 H/13 C/15 N chemical shift assignment of therapeutic octreotide acetate performed at natural abundance.
(PubMed, Magn Reson Chem)
- "Octreotide acetate, the active pharmaceutical ingredient in the long-acting release (LAR) drug product Sandostatin®, is a cyclic octapeptide that mimics the naturally occurring somatostatin peptide hormone...Here, using state-of-the-art 1D and 2D homo- and heteronuclear NMR experiments, octreotide was fully assigned, including water exchangeable amide protons, in aqueous buffer except for 13 CO and 15 NH of F1, 15 NH of C2, and 15 NζHζ of K5 that were not observed because of water exchange or conformational exchange. The solution NMR spectra were then directly compared with 1D 1 H/13 C/15 N solid-state NMR (SSNMR) spectra showing the potential applicability of 13 C/15 N SSNMR for octreotide drug product characterization."
Journal
October 22, 2023
Quantitative spectrofluorimetric method for determination of octreotide acetate synthetic peptide derivative in pure and its Sandostatin ampules forms.
(PubMed, Spectrochim Acta A Mol Biomol Spectrosc)
- "Furthermore, this protocol could be perfectly applied for the quantitative estimation of octreotide in its ampoules with a high degree of accuracy and precision. As a result, a developed protocol is ideally appropriate for fast and simple octreotide quantitative estimation in quality control laboratories."
Journal
August 17, 2023
The effect of preoperative short-term octreotide treatment to surgery in thyrotropin-secreting pituitary adenomas: a retrospective cohort study.
(PubMed, BMC Endocr Disord)
- "Preoperative octreotide treatment for the purpose of reducing excessive thyroid hormones may not enhance surgical outcomes, and the duration of octreotide treatment needs to be extended to fully benefit from the tumor-shrinking effects of SSAs."
Journal • Retrospective data • Surgery • Oncology • Pituitary Gland Carcinoma
1 to 25
Of
58
Go to page
1
2
3